ClinicalTrials.gg
CompletedNCT03528629Updated Dec 2, 2024

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

An interventional study of Zolbetuximab in Gastric Cancer and Gastro-esophageal Junction (GEJ) Cancer, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Astellas Pharma Inc · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Stomach Neoplasms with a site in Japan — 33 open to participants now, 55 under way, 12 of them phase 3. Stomach Neoplasms · Japan.

Enrollment
146th of 162
18 · median 158
Started
2018
with 12 others
No phase
7 of 181
2 open now
Registered
101st of 181
by date

Among the 181 studies in Stomach Neoplasms with a site in Japan, this one is the 146th largest by enrollment of the 162 interventional ones that give a count, is one of 13 that started in 2018, is one of 7 with no phase, and was the 101st registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

33 of the 181 studies in Stomach Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Stomach Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and antitumor activity of IMAB362 in Japanese subjects with locally advanced or metastatic Gastric or GEJ adenocarcinoma whose tumors have Claudin (CLDN) 18.2 Expression. This study will also assess pharmacokinetics and immunogenicity of IMAB362.

Read the detailed description

This study consists of two parts (Part 1: Safety; and Part 2: Expansion). First, the subjects will be enrolled in Safety Part with IMAB362 dose-1/2 (Arm A). Then the safety and tolerability of Arm A will be evaluated at Tolerability Evaluation Meeting (TEM). If there are no safety and tolerability concerns, enrollment for the Safety Part with IMAB362 dose-3 (Arm B) and the Expansion Part with IMAB362 dose-1/2 will be opened. For each part, participants who continue to derive clinical benefit and do not have intolerable toxicity from study treatment will be allowed to remain on treatment until treatment discontinuation criterion is met.

03

Conditions studied

  • Gastric Cancer
  • Gastro-esophageal Junction (GEJ) Cancer

Keywords

  • zolbetuximab
  • IMAB362
  • pharmacokinetics
  • tolerability
  • safety
  • ASP8951
  • immunogenicity
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has or cytologically confirmed diagnosis of gastric or gastro-esophageal junction adenocarcinoma.
  • Subject has gastric or gastroesophageal junction (GEJ) adenocarcinoma based on radiographic imaging or endoscopic examination.
  • Subject agrees not to participate in another interventional study while on treatment.
  • Subject has (ECOG) performance status 0-1.
  • Subject has predicted ≥ 12 weeks.
  • Subject must have an available tumor specimen collected at any time prior to the first dose of study treatment.
  • Subject must meet all of the pre-specified criteria on the laboratory tests that will be analyzed locally within 7 days prior to the first dose of study drug.
  • Locally advanced or gastric or GEJ adenocarcinoma with no standard of care treatment option or subject is ineligible to receive available standard of care treatment option.
  • Subject's tumor sample has Claudin (CLDN)18.2 membranous staining with any intensity as determined by central Immunohistochemistry (IHC) testing. (Safety part only)
  • Subject has CLDN18.2 high expression in ≥75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing. (Expansion Part Only)
  • Subject is an appropriate candidate for a tumor and is amenable to undergo a tumor biopsy during the Screening period and on-treatment tumor biopsy. (Expansion Part Only)
  • Subject has at least 1 according to (RECIST) 1.1 within 28 days prior to the first dose of study treatment. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. (Expansion Part Only)

Exclusion criteria

Exclusion Criteria:

  • Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies.
  • Subject has had radiotherapy within 2 weeks prior to first dose of study drug. Subject who received palliative radiotherapy to peripheral bone within 2 weeks prior to first dose of study drug and has recovered from all acute toxicities is allowed.
  • Subject has received other agents or devices concurrently or within 4 weeks prior first dose of study drug.
  • Subject has received systemic therapy, including systemic 2 weeks prior to first dose of study drug. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent are allowed.
  • Subject has gastric outlet syndrome or persistent recurrent vomiting.
  • Subject has uncontrolled or significant gastrointestinal hemorrhage.
  • Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Subject has a known history of a positive test for (HIV) infection.
  • Subject has a positive test for surface antigen (HBsAg) or virus antibody (anti-HCV). Subjects who are negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, hepatitis B virus deoxyribonucleic acid (DNA) test will be performed and if positive will be excluded. Subjects with positive serology but negative HCV ribonucleic acid (RNA) test results are eligible.
  • Subject has had within 6 months prior to first dose of study treatment any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure
  • Subject has active infection requiring systemic therapy.
  • Subject has other disease or co-morbidity, which may adversely affect the safe delivery of treatment within this trial.
  • Subject has psychiatric illness or social situations that would preclude study compliance.
  • Subject has active disease that has required systemic immunosuppressive treatment in the past 2 years.
  • Subject has had a major surgical procedure within 28 days prior to the first dose of study drug.
  • Subject has Fridericia- interval (QTcF) > 450 msec for males and > 470 msec for females on 12-lead (ECG) at screening based on local testing.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Subject has another active which is likely to require treatment.
  • Subjects who find it difficult to adhere to the provisions of treatment and observation specified in the protocol.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Safety Part Arm A (IMAB362 dose-1/2)

    Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.

    Drug: Zolbetuximab

  • Experimental
    Safety Part Arm B (IMAB362 dose-3)

    Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).

    Drug: Zolbetuximab

  • Experimental
    Expansion Part (IMAB362 dose-1/2)

    Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.

    Drug: Zolbetuximab

Interventions

  • Zolbetuximab will be administered as a 2-hour intravenous infusion.

    Also known as: IMAB362

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT) in Safety Part

    Any of the IMAB362 related AEs specified as the DLTs will be assessed during the first 3 weeks.

    Time frame: Up to Day 22

  2. Safety and tolerability assessed by incidence of adverse events (AEs) in Safety Part

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) guidelines (Version 4.03).

    Time frame: Up to 16 months

  3. Number of participants with laboratory test abnormalities in Safety Part

    Number of participants with potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to 14 months

  4. Number of participants with body weight abnormalities in Safety Part

    Number of participants with potentially clinically significant body weight change will be reported as AEs.

    Time frame: Up to 14 months

  5. Number of participants with vital sign abnormalities in Safety Part

    Number of participants with potentially clinically significant vital sign values will be reported as AEs.

    Time frame: Up to 14 months

  6. Number of participants with 12-lead electrocardiogram (ECG) abnormalities in Safety Part

    ECGs will be recorded with the participant in the supine position, after the subject has been lying down for approximately 5 minutes. Any clinically significant adverse changes on the ECG will be reported as AEs.

    Time frame: Up to 14 months

  7. Safety assessed by Eastern Cooperative Oncology Group (ECOG) performance status in Safety Part

    Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: Up to 14 months

  8. Objective Response Rate (ORR) by local review in Expansion Part

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

    Time frame: Up to 13 months

Secondary outcomes

  1. ORR by local review in Safety Part

    ORR is defined as the proportion of participants who have a best overall response of CR or PR per RECIST 1.1.

    Time frame: Up to 13 months

  2. ORR by central review in Expansion Part

    ORR is defined as the proportion of participants who have a best overall response of CR or PR per RECIST 1.1.

    Time frame: Up to 13 months

  3. Disease Control Rate (DCR) in Safety Part and Expansion Part

    DCR is defined as the proportion of participants who have a best overall response of CR, PR or stable disease (SD) per RECIST 1.1.

    Time frame: Up to 13 months

  4. Progression Free Survival (PFS) in Safety Part and Expansion Part

    PFS is defined as the time from the date of first dosing until the date of radiological or clinical progressive disease per RECIST 1.1 or death from any cause, whichever is earliest.

    Time frame: Up to 13 months

  5. Overall Survival (OS) in Safety Part and Expansion Part

    OS is defined as the time from the date of randomization until the date of death from any cause.

    Time frame: Up to 23 months

  6. Duration of Response (DOR) in Safety Part and Expansion Part

    DOR is defined as the time from the date of the first response (CR or PR) per RECIST 1.1 to the date of radiological progression or death, whichever occurs earlier.

    Time frame: Up to 13 months

  7. Pharmacokinetics (PK) of IMAB362 in Safety Part and Expansion Part: Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)

    AUCinf will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  8. PK of IMAB362 in Safety Part and Expansion Part: Percentage of AUCinf (AUCinf (%extrap))

    AUCinf (%extrap) will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  9. PK of IMAB362 in Safety Part and Expansion Part: AUC from the time of dosing to the last measurable concentration (AUClast)

    AUClast will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  10. PK of IMAB362 in Safety Part and Expansion Part: AUC from the time of dosing to the start of the next dosing interval (AUCtau)

    AUCtau will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  11. PK of IMAB362 in Safety Part and Expansion Part: Maximum concentration (Cmax)

    Cmax will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  12. PK of IMAB362 in Safety Part and Expansion Part: Concentration immediately prior to dosing at multiple dosing (Ctrough)

    Ctrough will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  13. PK of IMAB362 in Safety Part and Expansion Part: Time of the maximum concentration (tmax)

    tmax will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  14. PK of IMAB362 in Safety Part and Expansion Part: Terminal elimination half-life (t1/2)

    t1/2 will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  15. PK of IMAB362 in Safety Part and Expansion Part: Clearance (CL)

    CL will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  16. PK of IMAB362 in Safety Part and Expansion Part: Apparent volume of distribution at steady state (Vss)

    Vss will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  17. PK of IMAB362 in Safety Part and Expansion Part: Apparent volume of distribution during the terminal phase (Vz)

    Vz will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  18. PK of IMAB362 in Safety Part and Expansion Part: Accumulation ratio calculated using AUC (Rac(AUC))

    Rac(AUC) will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  19. PK of IMAB362 in Safety Part and Expansion Part: Rac (Cmax)

    Rac(Cmax) will be derived from the PK serum samples collected.

    Time frame: Up to 3 months

  20. Safety assessed by incidence of AEs in Expansion Part

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded using the CTCAE guidelines (Version 4.03).

    Time frame: Up to 16 months

  21. Number of participants with laboratory test abnormalities in Expansion Part

    Number of participants with potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to 14 months

  22. Number of participants with vital sign abnormalities in Expansion Part

    Number of participants with potentially clinically significant vital sign values will be reported as AEs.

    Time frame: Up to 14 months

  23. Number of participants with body weight abnormalities in Expansion Part

    Number of participants with potentially clinically significant body weight change will be reported as AEs.

    Time frame: Up to 14 months

  24. Number of participants with 12-lead ECG abnormalities in Expansion Part

    ECGs will be recorded with the participant in the supine position, after the subject has been lying down for approximately 5 minutes. There should be at least 2 minutes between ECG measurements in case a repeat is needed. Any clinically significant adverse changes on the ECG will be reported as AEs.

    Time frame: Up to 14 months

  25. Safety assessed by ECOG performance status in Expansion Part

    Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: Up to 14 months

  26. Frequency of anti-drug antibody (ADA)-positive participants in Safety Part and Expansion Part

    Immunogenicity of IMAB362 will be assessed by the frequency of ADA-positive participants.

    Time frame: Up to 16 months

07

Study locations

1 site
  • Site JP00001
    Kashiwa, Chiba, Japan
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jun 2020, 24 months.

Of 367 interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2018
First posted
May 18, 2018
StartActual
Jun 8, 2018
Primary completionActual
Jun 9, 2020
CompletionActual
Jun 9, 2020
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03528629
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Jun 8, 2018
Primary completion
Jun 9, 2020
Completion
Jun 9, 2020
Last update
Dec 2, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion